Dr. Chantelle Thomas talks to Dr. Ingmar Gorman about concerns and methodological critiques of MDMA-assisted therapy, including historical boundary violations and inappropriate treatment of participants. They also address adverse event management, inner healing intelligence, and the importance of adapting language and approach to resonate with each individual participant. Additionally, they discuss the ethical complexities of conducting clinical trials, including balancing participant privacy and safety with the need to share information for public advocacy and education. Finally, they delve into the intricacies of trauma therapy, including personal experiences, clinical approaches, and limitations, and emphasize the need for a paradigm shift in clinical practice, prioritizing the client's agency and internal resources for healing.

(0:00:00) Introduction

(0:10:14) FDA's decision on MDMA therapy for PTSD, with focus on ICER and FDA advisory panel reports.

(0:15:21) The benefits and challenges of a clinical trial for treating PTSD.

(0:21:03) Conducting clinical trials with nuanced considerations for ethics, regulations, and participant experiences.

(0:31:52) Adverse events in the trial, with concerns about data accuracy and researcher bias.

(0:44:02) Suicidal ideation and its impact on mental health treatment.

(0:52:23) Clinical trial design and unblinding issues in PTSD treatment study.

(0:59:26) MDMA therapy for trauma, participants' experiences and criticisms.

(1:05:31) Trauma therapy effectiveness and the importance of considering other measures beyond PTSD symptoms.

(1:10:36) Inner healing intelligence in MDMA-assisted therapy.

(1:29:51) MDMA-assisted therapy for PTSD, including resourcing and adherence.

Dr. Chantelle Thomas, Executive Clinical Director Windrose Recovery: https://windroserecovery.com/

Integrata: www.integratahealing.com

Dr. Ingmar Gorman: https://www.ingmargorman.com/about

Lykos: https://lykospbc.com